All In MedTech

Device Trial Radar · NCT05316311

A Study of Implantation of CRENEOUS ENTERPRISE 2 Intracranial Stent in Participants With Severe Symptomatic Intracranial Atherosclerotic Stenosis

Implantation of CERENOVUS ENTERPRISE 2 Intracranial Stent in Patients With Severe Symptomatic Intracranial Atherosclerotic Stenosis: A Multicenter, Prospective and Single-Arm Study in China

Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

194

Actual

Start

May 24, 2022

Primary completion

Dec 24, 2025

Study completion Dec 24, 2025

Sponsor

Lead sponsor
Medos International SARLNot on our public-company list
Sponsor type
Industry
First posted
Apr 7, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and effectiveness of CERENOVUS ENTERPRISE 2 intracranial stent implantation in treatment of participants with severe symptomatic intracranial atherosclerotic stenosis.

Conditions

  • Intracranial Atherosclerosis

Interventions

  • CERENOVUS ENTERPRISE 2 Intracranial StentDevice

    CERENOVUS ENTERPRISE 2 Intracranial Stent will be used to treat severe symptomatic intracranial artery stenosis.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with In-Stent RestenosisTime frame: At 12 months post-procedure

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Xuanwu Hospital, Capital Medical University

    Beijing, China

  • West China Hospital of Sichuan University

    Chengdu, China

  • Haikou People's Hospital

    Haikou, China

11 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.